Compare VTRS & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTRS | EVR |
|---|---|---|
| Founded | 1961 | 1995 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 14.4B |
| IPO Year | 2019 | 2006 |
| Metric | VTRS | EVR |
|---|---|---|
| Price | $15.72 | $314.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $11.83 | ★ $344.00 |
| AVG Volume (30 Days) | ★ 10.0M | 617.1K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.21% | 1.09% |
| EPS Growth | N/A | ★ 54.74 |
| EPS | N/A | ★ 14.05 |
| Revenue | ★ $14,299,900,000.00 | $3,880,084,000.00 |
| Revenue This Year | N/A | $22.39 |
| Revenue Next Year | $1.60 | $13.37 |
| P/E Ratio | ★ N/A | $21.78 |
| Revenue Growth | N/A | ★ 29.49 |
| 52 Week Low | $6.85 | $148.63 |
| 52 Week High | $16.47 | $388.71 |
| Indicator | VTRS | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 41.51 |
| Support Level | $9.63 | $295.21 |
| Resistance Level | $16.30 | $320.26 |
| Average True Range (ATR) | 0.51 | 17.01 |
| MACD | -0.14 | -1.78 |
| Stochastic Oscillator | 56.25 | 23.29 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.